Sectors

TIL
Instil Bio, Inc.
7.25
5 x 7.25
1 x 7.46
bid
ask
+
0.00
0.00%
09:56 AM
timesize
Ytd-34.09%
1y-74.51%
7.28
day range
7.38
5.67
52 week range
33.83
Open7.28Prev Close7.25Low7.28High7.38Mkt Cap49.17M
Vol221.00Avg Vol21.58KEPS-7.08P/E-1.02Forward P/E-1.80
Beta1.90Short Ratio2.29Inst. Own80.70%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning03-0450-d Avg7.84200-d Avg10.151yr Est100.33

TIL News

Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)
seekingalpha.com
Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)

Iovance Biotherapeutics is showing steady operational and financial progress, supporting a speculati

12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session

Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
globenewswire.com
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12

Next-Generation Platform Expands into Solid Tumors  Representing 100,000+ U.S. Deaths Annually SAN C

Earnings Scheduled For May 15, 2026
benzinga.com
Earnings Scheduled For May 15, 2026

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology

Earnings Scheduled For March 27, 2026
benzinga.com
Earnings Scheduled For March 27, 2026

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
globenewswire.com
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of stra

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
globenewswire.com
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue

50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. -

NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. -

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. -

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. -

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. -

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

TIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & Korsinsky
newsfilecorp.com
TIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & Korsinsky

New York, New York--(Newsfile Corp. - January 20, 2026) - Levi & Korsinsky notifies investors that i

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. -

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. -

NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. -

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. -

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Instil Bio shares slide on discontinuation of lead clinical programs
proactiveinvestors.com
Instil Bio shares slide on discontinuation of lead clinical programs

Instil Bio (NASDAQ:TIL) shares plummeted 46% to about $7 after the company announced its decision to

Instil Bio Pulls Plug On Lead Drug Development
benzinga.com
Instil Bio Pulls Plug On Lead Drug Development

Instil Bio, Inc. (NASDAQ: TIL) stock is trading lower on Tuesday. Axion Bio Inc., a wholly-owned sub

Instil Bio shares slide on discontinuation of lead clinical programs
proactiveinvestors.com
Instil Bio shares slide on discontinuation of lead clinical programs

Instil Bio (NASDAQ:TIL) shares plummeted 46% to about $7 after the company announced its decision to

Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
globenewswire.com
Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Col

DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced

Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

DALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stag

Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  On Thursday, 241 companies hit new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Monday

  Monday saw 196 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  On Wednesday, 807 companies reached new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Friday

  On Friday, 1043 companies hit new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  During Thursday, 849 stocks hit new 52-week lows.